CTLA4Ig-gene transfection inhibits obliterative airway disease in rats

Annals of Thoracic Surgery

Volumn 75, Issue 4, 2003, Pages 1123-1127

  Kita, Yusuke ^a   Suzuki, Kazuya ^b   Nogimura, Hiroshi ^b   Takahashi, Tsuyoshi ^b   Kazui, Teruhisa ^b  

^a Haibara General Hospital   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ALLOGRAFT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; GENETIC TRANSFECTION; HETEROTOPIC TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; ISOGRAFT; MALE; MONONUCLEAR CELL; NONHUMAN; OBLITERATIVE AIRWAY DISEASE; PRIORITY JOURNAL; RAT; RECIPIENT; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; TRACHEA;

ADENOVIRIDAE; ANIMALS; BRONCHIOLITIS OBLITERANS; GENE THERAPY; IMMUNOCONJUGATES; LAC OPERON; LUNG TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RATS; RATS, INBRED LEW; TRANSFECTION;

EID: 0037383664     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)04707-0     Document Type: Article

References (23)

1. Burke CMJ, Theodore K, Dawkins D, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984;86:824-32.
2. Griffith BP, Paradis IL, Zeevi A, Rabinowich H, Yousem SA. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg 1988;208:371-8.
3. Milne DS, Gascoigne A, Wilkes J, et al. The immunohistopathology of obliterative bronchiolitis following lung transplantation. Transplantation 1992;54:748-50.
4. Sharpies LD, Scott JP, Dennis C. Risk factors for survival following combined heart-lung transplantation. Transplantation 1994;57:218-23.
5. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4-13.
6. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114:195-202.
7. Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Transplantation 1996;61:427-30.
8. Dusmet M, Maurer J, Winton T, Kesten S. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 1996;15:948-54.
9. Hertz MI, Jessurun J, King MB, Savik SK, Murray J. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993;142:1945-51.
10. al-Dossari GA, Jessurun J, Bolman RM, et al. Pathogenesis of obliterative bronchiolitis: possible roles of platelet-derived growth factor and basic fibroblast growth factor. Transplantation 1995;59:143-5.
11. Kelly KE, Hertz MI, Mueller DL. T-cell and major histocompatibility complex requirements for obliterative airway disease in heterotopically transplanted murine tracheas. Transplantation 1998;66:764-71.
12. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
13. Wu Y, Guo Y, Liu Y. A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7. J Exp Med 1993;178:1789-93.
14. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-92.
15. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11102-5.
16. Sayegh MH, Zheng X-G, Magee C, Hancock WW, Turka LA. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 1997;64:1646-50.
17. Pearson TC, Alexander DZ, Corbascio M, et al. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997;63:1463-9.
18. Glysing-Jensen T, Raisanen-Sokolowski A, Sayegh MH, Russell ME. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class 1 and 2 incompatible mouse heart allografts. Transplantation 1997;64:1641-5.
19. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-6.
20. Namii Y, Hayashi S, Yokoyama I, et al. Evidence that the adenoviral vector containing the CTLA4-Ig gene improves transgene expression and graft survival. Transplant Proc 1997;29:1738-9.
21. Kita Y, Li X-K, Ohba M, et al. Prolonged cardiac allograft survival in rats systemically injected adenoviral vectors containing CTLA4Ig-gene. Transplantation 1999;68:758-66.
22. Romaniuk A, Prop J, Petersen AH, Wildevuur CRH, Nieuwenhuis P. Expression of class II major histocompatibility complex antigens by bronchial epithelium in rat lung allografts. Transplantation 1987;44:209-14.
23. Prop J, Jansen HM, Wildevuur CRH, Nieuwenhuis P. Lung allograft rejection in the rat: V. Inhaled stimuli aggravate the rejection response. Am Rev Respir Dis 1985;132:168-72.